Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
The investigational therapy ITM-11 has shown promising results in the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients
In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.”
The Neuroendocrine Tumor Research Foundation (NETRF) has announced our newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising
A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type
NETRF was well-represented at NANETS 2024, the annual meeting of the North American Neuroendocrine Tumor Society held in November. Several hundred physicians, researchers, and patient
NETRF’s 2024 Margie & Robert E. Petersen Neuroendocrine Tumor Research Symposium was held October 28-30 at The Hotel Commonwealth in Boston, Massachusetts. Our Symposium brought
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) and NETRF are proud to announce that Dr. Ajay Kumar Sharma has been
A new study has revealed that certain bone marrow cells may absorb more radiation during radiopharmaceutical therapy (RPT) than previously believed. This finding could explain
The investigational drug cabozantinib (CABOMETYX®) has significantly improved outcomes for those living with advanced neuroendocrine tumors (NETs), according to the latest results from the Phase